Cardiology

Long-Term Evolocumab Safe and Effective for Treating Hypercholesterolemia



Evolocumab consistently reduced LDL-C with no increase in adverse events over a 5-year study period.

Source link

Related posts

JACC Instructions for Authors

Newsemia

Translating the Translation: What Clinicians Should Know About the Fourth Universal Definition of Myocardial Infarction

Newsemia

Maternal Exposure to Ambient Particulate Matter

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy